BR9901279A - Triciclicos substituìdos - Google Patents

Triciclicos substituìdos

Info

Publication number
BR9901279A
BR9901279A BR9901279-0A BR9901279A BR9901279A BR 9901279 A BR9901279 A BR 9901279A BR 9901279 A BR9901279 A BR 9901279A BR 9901279 A BR9901279 A BR 9901279A
Authority
BR
Brazil
Prior art keywords
tricycles
replaced
tricyclics
compounds
treatment
Prior art date
Application number
BR9901279-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Benjamin Alan Anderson
Michael Leroy Phillips
Nicholas James Bach
Michael Enrico Richett
Jolie Anne Bastian
Daniel Jon Sall
Nancy Kay Harn
Jason Scott Sawyer
Richard Waltz Harper
Richard Walter Schevitz
Gary Alan Hite
Robert Theodore Vasileff
Michael Dean Kinnnick
Ho-Shen Nmn Lin
Richard James Loncharich
John Mcneill Mcgill Iii
Edward David Mihelich
John Michael Junior Morin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9901279A publication Critical patent/BR9901279A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9901279-0A 1998-04-17 1999-04-16 Triciclicos substituìdos BR9901279A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
BR9901279A true BR9901279A (pt) 2000-05-02

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9901279-0A BR9901279A (pt) 1998-04-17 1999-04-16 Triciclicos substituìdos
BR9902365-2A BR9902365A (pt) 1998-04-17 1999-04-16 Tricìclicos substituìdos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9902365-2A BR9902365A (pt) 1998-04-17 1999-04-16 Tricìclicos substituìdos

Country Status (30)

Country Link
EP (2) EP0952149B1 (https=)
JP (2) JPH11322713A (https=)
KR (2) KR19990083232A (https=)
CN (1) CN1149193C (https=)
AR (2) AR018593A1 (https=)
AT (2) ATE271037T1 (https=)
AU (2) AU753436B2 (https=)
BR (2) BR9901279A (https=)
CA (2) CA2269246C (https=)
CO (2) CO5011054A1 (https=)
CZ (2) CZ137099A3 (https=)
DE (2) DE69917833T2 (https=)
DK (1) DK0950657T3 (https=)
DZ (1) DZ2769A1 (https=)
EA (2) EA002347B1 (https=)
ES (2) ES2222663T3 (https=)
HU (2) HUP9901220A3 (https=)
ID (2) ID23287A (https=)
IL (2) IL129483A0 (https=)
NO (2) NO314400B1 (https=)
NZ (3) NZ507564A (https=)
PE (2) PE20000432A1 (https=)
PL (2) PL332566A1 (https=)
PT (1) PT950657E (https=)
SG (2) SG81977A1 (https=)
SI (1) SI0950657T1 (https=)
TR (2) TR199900843A2 (https=)
TW (1) TWI238160B (https=)
YU (2) YU19199A (https=)
ZA (2) ZA992771B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
JP2004525154A (ja) * 2001-03-28 2004-08-19 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしての置換カルバゾール
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
MX2010010471A (es) 2008-03-26 2010-10-20 Daiichi Sankyo Co Ltd Derivado de tetrahidroisoquinolina novedoso.
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010084402A2 (en) * 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
KR20150088802A (ko) 2012-11-30 2015-08-03 지이 헬쓰케어 리미티드 트리시클릭 인돌 유도체의 결정화 방법
IN2015DN03939A (https=) * 2012-11-30 2015-10-02 Ge Healthcare Ltd
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5472978A (en) * 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE69610793T2 (de) * 1995-06-23 2001-05-03 Eli Lilly And Co., Indianapolis 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
AU1289797A (en) * 1995-12-13 1997-07-03 Eli Lilly And Company Naphthyl acetamides as spla2 inhibitors
JP2001503055A (ja) * 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
CN1149193C (zh) 2004-05-12
NO991821D0 (no) 1999-04-16
AU753547B2 (en) 2002-10-24
SI0950657T1 (en) 2005-02-28
PL332565A1 (en) 1999-10-25
CA2269262A1 (en) 1999-10-17
CA2269246C (en) 2009-08-25
TWI238160B (en) 2005-08-21
HU9901220D0 (en) 1999-06-28
EA199900301A3 (ru) 2000-04-24
EP0952149A2 (en) 1999-10-27
AU2381999A (en) 1999-10-28
HUP9901220A3 (en) 2001-11-28
YU19199A (sh) 2002-08-12
NO312240B1 (no) 2002-04-15
TR199900843A2 (xx) 2000-02-21
PE20000476A1 (es) 2000-06-02
ATE268756T1 (de) 2004-06-15
ES2222663T3 (es) 2005-02-01
AR018593A1 (es) 2001-11-28
EA002347B1 (ru) 2002-04-25
EP0950657B1 (en) 2004-07-14
EP0950657A3 (en) 2001-08-16
EA002816B1 (ru) 2002-10-31
CZ136999A3 (cs) 1999-11-17
NZ335253A (en) 2000-11-24
CO5011054A1 (es) 2001-02-28
TR199900853A3 (tr) 1999-11-22
EP0950657A2 (en) 1999-10-20
NO314400B1 (no) 2003-03-17
SG81976A1 (en) 2001-07-24
PL332566A1 (en) 1999-10-25
AU2381799A (en) 1999-10-28
ZA992772B (en) 2002-07-16
SG81977A1 (en) 2001-07-24
YU18999A (sh) 2002-08-12
PT950657E (pt) 2004-11-30
HU9901220A (hu) 2000-04-28
ID23761A (id) 2000-05-11
DE69918590D1 (de) 2004-08-19
KR19990083232A (ko) 1999-11-25
PE20000432A1 (es) 2000-05-23
HU9901221D0 (en) 1999-06-28
IL129485A0 (en) 2000-02-29
EP0952149A3 (en) 2001-08-16
ID23287A (id) 2000-04-05
KR100586761B1 (ko) 2006-06-08
DE69918590T2 (de) 2005-07-21
ES2226286T3 (es) 2005-03-16
DE69917833D1 (de) 2004-07-15
DK0950657T3 (da) 2004-11-22
BR9902365A (pt) 2001-04-24
JP2000026416A (ja) 2000-01-25
DE69917833T2 (de) 2005-07-14
JPH11322713A (ja) 1999-11-24
EA199900303A2 (ru) 1999-10-28
EA199900303A3 (ru) 2000-04-24
AR018186A1 (es) 2001-10-31
KR19990083233A (ko) 1999-11-25
NO991822D0 (no) 1999-04-16
TR199900853A2 (xx) 1999-11-22
HU9901221A (hu) 2000-04-28
EA199900301A2 (ru) 1999-10-28
JP4435330B2 (ja) 2010-03-17
HUP9901221A3 (en) 2001-11-28
CZ137099A3 (cs) 1999-11-17
CA2269246A1 (en) 1999-10-17
ATE271037T1 (de) 2004-07-15
CN1253948A (zh) 2000-05-24
DZ2769A1 (fr) 2003-12-01
NO991821L (no) 1999-10-18
EP0952149B1 (en) 2004-06-09
CO5031247A1 (es) 2001-04-27
NO991822L (no) 1999-10-18
IL129483A0 (en) 2000-02-29
NZ507564A (en) 2002-10-25
AU753436B2 (en) 2002-10-17
ZA992771B (en) 2002-04-18
NZ335251A (en) 2000-11-24

Similar Documents

Publication Publication Date Title
BR9901279A (pt) Triciclicos substituìdos
BR9713261A (pt) Tricìclicos substituìdos
ES2186720T3 (es) Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
BR9900320A (pt) Composição antimicrobiana
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
ES2192301T3 (es) Derivados de resorcinol.
NO20015417D0 (no) Behandling av autoimmune sykdommer med antagonister som binder til B-celleoverflatemarkörer
BR9714002A (pt) Pirróis como inibidores de spla2
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
BR0114630A (pt) Secretagogos de hormÈnio do crescimento
FI971489A0 (fi) Uusia bentsoksatsoleja
BR9901275A (pt) Triciclicos substituidos.
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
SE9901077D0 (sv) Novel use
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
SE9801494D0 (sv) Novel use
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
SV2002000041A (es) Derivados de resorcinol ref. pc10529/82897/bb
BR9713562A (pt) Fenil glioxamidas como inibidores de spla2
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
BR9713987A (pt) Fenil acetamidas como inibidores de spla2
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
ECSP003590A (es) Compuestos calcioliticos
DE69910432D1 (de) Substituierte pyrroloindole

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO NO INPI - RJ 017762 DE 09/04/2002, A REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO SOBRE UM QUADRO COM 23 ( VINTE E TRES ) REIVINDICACOES E EFETUOU A RETRIBUICAO EQUIVALENTE A 23 ( VINTE E TRES ) REIVINDICACOES. ENTRETANTO, NO ULTIMO QUADRO REINVINDICATORIO APRESENTANDO ATRAVES DA PETICAO NO INPI-RJ 052474 EM 29/10/2001, CONSTAM 25 ( VINTE E CINCO) REIVINDICACOES. DESSE MODO, PARA QUE POSSAMOS FAZER O EXAME DE MERITO PEDIDO E NECESSARIO QUE A REQUERENTE ESCLARECA SE DESEJA QUE O EXAME SEJA FEITO COM BASE NESTE ULTIMO QUADRO, DEVENDO, PARA TANTO, COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 02 ( DUAS ) REIVINDICACOES EXCEDENTE.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL: CO7D 209/88; A61K 31/40; C07D 209/82; A61K 31/403; A61K 31/44; A61K 31/4427; A61K 31/443; A61K 31/4439; A61P 1/00; A61P 7/00; A61P 9/00; A61P 11/00; A61P 11/06; A61P 19/02; A61P 31/00; A61P 31/04; A61P 35/00; A61P 43/00

Ipc: C07D 209/82 (2008.04), A61K 31/40 (2008.04)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 14A E 15A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ATE A 21A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.